Article
Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus.
Gene therapy - 1 May 2015
Zhen S, Hua L, Liu Y-H, Gao L-C, Fu J, Wan D-Y, Dong L-H, Song H-F, Gao X
Abstract excerpt
The current therapies to treat hepatitis B virus (HBV) infection are limited. Recently, clustered regularly interspaced short palindromic repeat (CRISPR) systems, originally identified in bacteria and archaea, have been found to consist of an RNA-based adaptive immune system that degrades complimentary sequences of invading plasmids and viruses. Here, we studied the effects of the CRISPR/CRISPR-associated Cas9...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.